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ABSTRACT
Abnormal metabolism is an emerging hallmark of cancer. Cancer cells utilize both
aerobic glycolysis and oxidative phosphorylation (OXPHOS) for energy production and
biomass synthesis. Understanding the metabolic reprogramming in cancer can help
design therapies to target metabolism and thereby to improve prognosis. We have
previously argued that more malignant tumors are usually characterized by a more
modular expression pattern of cancer-associated genes. In this work, we analyzed the
expression patterns of metabolism genes in terms of modularity for 371 hepatocellular
carcinoma (HCC) samples from the Cancer Genome Atlas (TCGA). We found that
higher modularity significantly correlated with glycolytic phenotype, later tumor
stages, higher metastatic potential, and cancer recurrence, all of which contributed
to poorer prognosis. Among patients with recurred tumors, we found the correlation of
higher modularity with worse prognosis during early to mid-progression. Furthermore,
we developed metrics to calculate individual modularity, which was shown to be
predictive of cancer recurrence and patients’ survival and therefore may serve as a
prognostic biomarker. Our overall conclusion is that more aggressive HCC tumors, as
judged by decreased host survival probability, had more modular expression patterns
of metabolic genes. These results may be used to identify cancer driver genes and
for drug design.

INTRODUCTION

fetoprotein) and miR-21 [4]. However, HCC can result from a
variety of risk factors, such as hepatitis B/C virus or alcoholic
liver disease [5], which makes it difficult to characterize
HCC with single gene biomarkers. One key to a further
breakthrough in HCC therapy lies in better understanding the
underlying mechanism of HCC progression.
In recent years, a significant amount of research
has gone into analyzing cancer-associated pathways and

Hepatocellular carcinoma (HCC) is a primary
malignancy of the liver, with average survival time between
6 to 20 months without any intervention [1]. It is also the
third leading cause of cancer mortality worldwide [2]. The
prognosis for HCC patients remains poor [3]. Diagnosis of
HCC is usually based on biomarkers, such as AFP (alphawww.oncotarget.com
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networks to gain insight into the complex biological
systems underlying tumor progression [6, 7]. One
promising approach for breast cancer and leukemia
patients has been to identify the varying patterns of
cancer-associated gene expression to predict prognosis
[8, 9]. In both examples, the level of organization of
the cancer-associated gene network, as measured by the
cophenetic correlation coefficient (CCC), was shown to
be correlated with cancer risk, progression and prognosis.
Inspired by these works, we here aim to characterize HCC
progression and patient survival by analyzing the structure
of the cancer-associated gene network in HCC.
Liver is an organ in which metabolism plays a key
role. And abnormal metabolism is a hallmark of cancer [10,
11]. Therefore, we chose to analyze the expression patterns
of metabolic genes in HCC patients. Unlike normal
cells, cancer cells use glycolysis for energy production
irrespective of the availability of oxygen, a process that is
referred to as the Warburg effect or aerobic glycolysis [12,
13]. Interestingly, although aerobic glycolysis has been
regarded as the dominant metabolism phenotype in cancer,
recent experimental evidence shows that mitochondria are
actively functional in cancer cells [14–16], and oxidative
phosphorylation (OXPHOS) can enhance metastasis in
certain scenarios [17–19]. Study of the interplay between
glycolysis and OXPHOS will deepen our understanding of
cancer metabolism and metastasis.
To quantify the activities of the two main metabolism
phenotypes in HCC, OXPHOS and glycolysis, Yu
et al. [20] developed the AMPK and HIF-1 signatures
by evaluating the expression of the downstream genes
of AMPK (5′ AMP-activated protein kinase) and HIF1 (hypoxia-inducible factor 1), in total 33 AMPK
downstream genes and 23 HIF-1 downstream genes. The
AMPK and HIF-1 signatures have been shown to capture
the highly significant metabolic features of HCC samples
[20]. In addition, the AMPK and HIF-1 signatures can
associate the metabolism phenotypes of HCC samples
with oncogene activities, such as MYC, c-SRC and RAS,
which further validates the use of the AMPK and HIF-1
signatures in characterizing the metabolic activity of HCC
samples [20]. Based on these arguments, the AMPK and
HIF-1 downstream genes were chosen for the present study
as a relevant set of cancer-associated genes for HCC. The
strong anti-correlation between AMPK and HIF-1 activities
in HCC [20] suggests the expression of these metabolic
genes is modular, with the AMPK and HIF-1 downstream
gene subsets as two likely modules (Figure 1A).
Community structure of a gene network conveys
information regarding the interaction between genes. In
particular, genes within the same community cooperate
much more with each other than with those in other
communities. Here we utilize modularity to quantify
the community structure of the metabolic gene network
in HCC. Modularity is a measure of intracommunity
connection strength compared to what is expected
www.oncotarget.com

from randomly distributed connections [21, 22]. In
the current context, it quantifies the ability of tumor
cells to organize individual cancer-associated genes
so as to maximize network efficiency. Modularity is
present in almost all biological systems, from molecular
interactions to macroscopic food webs [23, 24]. A general
theory regarding modularity shows that high modularity
systems afford greater evolutionary fitness in high stress
environments or over shorter time scales, whereas low
modularity systems afford greater fitness in low stress
environments or over longer time scales [25, 26]. This
general principle can be applied to understand the relation
between modularity of cancer-related gene networks and
the aggressiveness of cancer [8, 9]. Using this theory,
we predict that tumors with a more modular expression
pattern of cancer-associated genes, organized to counteract
host defenses, are more fit and aggressive. At longer time
scales, tumor growth overcomes host defenses and loses
its sensitivity to host actions, and modularity is predicted
to decline.
In this work, we analyzed the change of the modular
expression pattern of the AMPK and HIF-1 downstream
genes in HCC samples as a function of metabolism
phenotypes, tumor stages, metastatic potentials and
tumor recurrence. We found that (i) HCC samples with a
glycolysis phenotype show significantly higher modularity
than samples with an OXPHOS phenotype; (ii) HCC
samples at tumor stages II-IV have significantly higher
modularity than samples at stage I; (iii) HCC samples
with higher metastatic potential maintain significantly
higher modularity than samples with lower metastatic
potential; and (iv) patients that have recurrence within
12, 24 or 36 months have significantly higher modularity
than those with no recurrence within the same amount
of time. These results confirm the theoretical prediction
that more aggressive tumors correspond to a more
modular interaction pattern of the cancer-associated gene
network. We also found that modularity increases with
tumor progression up to 8 months before recurrence, but
then decreases. This result is examined in detail in the
‘Discussion’ section, and indicates that modularity is no
longer selected for at very late stages of tumor progression.
This result is also in accord with the aforementioned
theoretical expectations. We further developed metrics
to calculate individual modularity, which proved to be
predictive of recurrence and survival for individual HCC
patients. Possible applications of modularity in terms of
drug design and identifying cancer-related genes will be
discussed in the ‘Discussion’ section.

RESULTS
To construct our HCC cancer-associated gene
network, we took the 33 AMPK downstream genes and
23 HIF-1 downstream genes identified by Yu et al. [20]
as nodes in the network. For each group of patients,
15016
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the interaction patterns between genes were calculated
using Pearson correlation. Simply put, two genes have
a strong interaction if they show a similar trend of gene
expression changing across patients. That is, if one gene
expression increases and another gene expression also
increases, then these genes are cooperating and strongly
interacting with each other. After nodes and links were
established, we applied the Newman algorithm [22] to
obtain the community structure of the gene network and
the corresponding modularity value.

HIF-1 axes, each HCC sample was assigned a metabolic
state of glycolysis (HIF-1high/AMPKlow), hybrid (HIF-1high/
AMPKhigh) or OXPHOS (HIF-1low/AMPKhigh) through
k-means clustering using the sum of absolute differences
(Figure 2A). Group modularity calculation showed that the
OXPHOS group had the lowest mean modularity and the
glycolysis group had the highest mean modularity (Figure
2B). Combined with survival curves of the three groups
(Figure 2C), it is clear that the glycolysis group had the
worst survival and OXPHOS the best, with hybrid in the
middle, indicating that higher modularity corresponded to
a more aggressive tumor. In Figure 2B and for all bar plots
below, the error bars are obtained through the bootstrapping
method. To obtain the significance levels, we used the
method described in the ‘Materials and Methods’ section.

Modular expression pattern of the AMPK and
HIF-1 downstream genes
There exists a strong anti-correlation between the
AMPK activity and HIF-1 activity across all 371 HCC
samples (Figure 1A). In addition, expression of individual
AMPK downstream genes was highly positively
correlated within the AMPK gene group and negatively
correlated with the HIF-1 downstream genes, and vice
versa (Figure 1B). The expression pattern of these genes
was highly modular and consisted of two modules, one
containing mainly AMPK downstream genes and the other
HIF-1 downstream genes, as identified by the Newman
algorithm (Figure 1C).

HCC samples at later tumor stage have higher
modularity
To analyze the change of modularity with respect
to tumor stage, we classified the 348 of the 371 HCC
samples that have neoplasm disease stage information into
two groups, stage I (171 samples) and stage II-IV (177
samples). This was done to ensure that each group has
similar number of samples. Group modularity calculations
show that the HCC samples in the stage II-IV group had
a significantly higher mean modularity than the HCC
samples in the stage I group (Figure 3A). HCC samples at
stage II-IV had a significantly worse survival than samples
at stage I (Figure 3B), which further confirmed that higher
modularity corresponded to worse survival, i.e. a more
aggressive tumor.

Modularity and metabolism phenotypes
To evaluate the modular gene expression pattern
of different metabolism phenotypes of HCC samples, we
performed principal component analysis (PCA) on the
RNA-Seq data of 33 AMPK downstream genes and 23 HIF
downstream genes. Since AMPK and HIF-1 are master
regulators of OXPHOS and glycolysis, respectively [20],
the resulting first principal components (PC1s) for AMPK
and HIF-1 downstream genes were assigned as the axes
to quantify the activities of OXPHOS and glycolysis.
After projecting all 371 HCC samples to the AMPK and

HCC samples with higher metastatic potential
have greater modularity
Metastasis accounts for more than 90% of cancerrelated deaths [27]. To evaluate the correspondence of

Figure 1: Modular gene expression pattern of the metabolic genes. (A) Evaluation of the AMPK and HIF-1 activities in HCC

patients’ samples (n = 371, r = –0.59, p < 0.0001). Each point represents the AMPK and HIF-1 activities of one sample. (B) Correlation
matrix of the 33 AMPK downstream genes and 23 HIF-1 downstream genes. (C) Rearranged correlation matrix calculated from the
complete dataset of 371 HCC patients by the Newman algorithm. The Newman algorithm obtained a partition into two modules. Modules
are labeled by black dashed lines. The red dashed lines in (B) and (C) are the diagonal elements of the correlation matrix. The red color
corresponds to a correlation coefficient of 1, as each gene is fully correlated with itself. In modularity calculation, the diagonal elements
were set to 0, as it was assumed that there were no self-loops.
www.oncotarget.com
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modularity to metastatic potential of HCC samples, we
grouped the samples based on their metastatic potential
and calculated the group modularity. Genes SNRPF,
EIF4EL3, HNRPAB, DHPS, PTTG1, COL1A1, COL1A2,
LMNB1 (comprising the eight-gene signature) have
been shown to be upregulated in metastases compared
to primary tumor sites [28]. Expression levels of these
genes has been used to evaluate the metastatic potential
of primary tumors [28]. We here used the sum of log2transformed expression levels of these eight genes to
represent the metastatic potential of primary HCC samples.
The 123 samples with the lowest metastatic potential were
classified as the low potential group, and the 123 samples
with the highest metastatic potential as the high potential
group. Group modularity calculation results show that the
high metastatic potential group had higher modularity and
worse prognosis (Figure 4A). We also used the expression
of gene SPP1 to quantify the metastatic potential of HCC
samples since the single SPP1 gene has been shown to be a
diagnostic marker for metastatic HCC [29]. The grouping
of HCC samples by expression of SPP1 show consistent
results to that observed from the eight-gene signature

(Figure 4B). This result indicated that a highly modular
pattern of cancer-associated gene interactions may serve
as a sign of metastasis.

Modularity and tumor recurrence
Tumor relapse is a supreme clinical challenge
[30]. To analyze how tumor relapse is connected to the
modularity of metabolic genes in HCC samples, we
classified the 319 of 371 HCC samples that have tumor
recurrence information – ‘recurred’ or ‘disease free’. Here
the 319 samples were classified into non-recurrence and
recurrence groups within 12 months, 24 months, or 36
months respectively. For example, the recurrence group
within 12 months includes HCC samples whose diseasefree status was ‘recurred’ and the ‘disease free time’ was
shorter than 12 months. The non-recurrence group within
12 months includes HCC samples whose ‘disease free
time’ was longer than 12 months, with either ‘recurred’ or
‘disease free’ status.
In all three cases, we observed that the group of
HCC patients with recurred tumors had a higher mean

Figure 2: Modularity and metabolism phenotypes. (A) The 371 patients’ samples are clustered into three metabolism phenotypes:
OXPHOS (blue), hybrid (magenta), and glycolysis (red). (B) Group modularity of three metabolism phenotypes. Here, ʻ*’represents 0.01
< p ≤0.05, and ʻ**’represents 0.001 < p ≤0.01 If there is no labeling of the significance level, it means the difference is not significant. (C)
Kaplan-Meier overall survival curves of HCC patients in OXPHOS, hybrid and glycolysis.

Figure 3: Modularity and tumor stages. (A) Bar plot of the group modularity of HCC patients at stage I and that at stage II–IV. Here
ʻ***’ represents p ≤ 0.001. (B) Kaplan-Meier overall survival curves of HCC patients at stage I and stage II–IV.
www.oncotarget.com
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modularity than the group of patients without recurred
tumors (Figure 5A). The difference between the recurrence
and no-recurrence groups became more significant as time
increased from 12 to 24 to 36 months. The survival curves
confirmed that the recurrence group, which was also the
high modularity group, had poor survival (Figure 5A).
To understand the origin of the correlation between
higher modularity and worse survival, we examined the
relation between modularity and tumor recurrence time
among recurred patients. Among the 319 samples, 174
have disease-free status as ‘recurred’. After discarding
the 4 patients with the longest disease free time, the rest
were sorted based on the disease-free time and classified
into 5 groups – group 1, 2, 3, 4 and 5 with decreasing
disease-free time. That is, group 1 had the longest disease
free time before recurrence shortest disease free time
before recurrence. The result is shown in Figure 5B,
and the corresponding survival curves for each group
are shown in Figure 5C. Modularity first increased with
tumor progression, and then decreased. Even though
the differences between each group were not always
significant, the significant difference between group 1
and group 3 and between group 3 and group 5 strongly
supported this non-monotonic trend. It is also worth noting
that modularity correlated with worse survival for the first
3 groups, but the correlation is reversed for groups 4 and

5. This result is similar to the trend observed in a study
of acute myeloid leukemia [9]. At early stages, increased
modularity correlates with decreased survival as cancer
cells organize their gene expression against the host. At
later stages, cancer has overcome the host defenses, and
a high value of modularity is no longer selected for. Host
survival, while low, becomes independent of modularity.
We note that this crossover occurs rather late: recurrence
times for groups 1, 2, 3 were 90–22 months, 22–13
months, and 13–8 months; the recurrence times for groups
4 and 5 were 8–4 and 4–1 months, respectively. Note that
Figure 5B and 5C are based on patients with recurred
tumors only, whereas Figure 5A contains both recurred
patients and disease-free patients.

Clinical application of modularity: Individual
modularity and prediction
Calculation of group modularity is useful for
understanding the group differences of metabolic gene
expression patterns and the general relation between
modularity and malignancy. However, for clinical
application, individual modularity is required in order to
make predictions regarding individual prognosis.
The detailed definition and calculation procedure of
individual modularity can be found in the ‘Materials and

Figure 4: Modularity and metastatic potential. Left panel: Group modularity of HCC samples with low and high metastatic
potential evaluated by eight-gene signature (A) and SPP1 (B). Right panel: Kaplan-Meier overall survival curves of HCC patients with low
and high metastatic potential evaluated by eight-gene signature (A) and SPP1 expression (B). Here ʻ***’ represents p ≤ 0.001.
www.oncotarget.com
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Methods’ section. Simply put, we applied the Newman
algorithm to an individual cancer-associated gene network,
with a new method to define links and with an additional
de-noising step.
Individual modularity for all 371 samples ranged
from 0.248 to 0.652, with mean 0.453 and standard
deviation 0.079. These numbers appeared to be consistent
with modularity values found in other functional human
biological networks [31]. Modularity at the individual
level largely confirmed the above group-level trends of
modularity for HCC patients classified by metabolism
phenotypes, stage information, recurrence status and
metastatic potential. Higher individual modularity
corresponded to the glycolysis phenotype, Figure 6A, later
tumor stage, Figure 6B, tumor recurrence, Supplementary
Figure 2A–2C, and higher metastatic potential, as
determined by the eight-gene signature, Figure 6C, and
SPP1 expression, Supplementary Figure 2D and worse
patient survival, Supplementary Figure 3. Together,
these results validate the use of the metric of individual

modularity to evaluate the aggressiveness of individual
HCC patients.
To make prognostic predictions with individual
modularity, we focus on patients’ survival and tumor
recurrence. We attempted to predict the probability of
survival longer than 24 months and no recurrence in 12
months, so that each group has a comparable amount of
samples: survived longer than 24 months, 140 samples;
shorter than 24 months, 91 samples; no recurrence in 12
months, 176 samples; and recurrence within 12 months, 104
samples. We then divided patients into 6 groups based on
their individual modularity values: 0.24–0.31, 0.31–0.38,
0.38–0.45, 0.45–0.52, 0.52–0.59, and 0.59–0.66. For each
group, we counted the number of patients that survived
longer than 24 months and that remained disease-free for
more than 12 months. We then calculated the proportion
of these patients in each group, Figure 6D–6E, left panel.
Overall, the higher the modularity, the lower the survival
and disease-free probability. The only exception is the first
bar in Figure 6D left panel, which could be potentially due
to the very small number of 7 patients in the group.

Figure 5: Modularity and tumor recurrence. (A) Modularity (left panels) and Kaplan-Meier overall survival curves (right panels)
of patients that were stratified into recurrence and non-recurrence within 12, 24 and 36 months. (B) Non-monotonic change of modularity
with tumor recurrence time. Samples in group 1 have the longest recurrence time and samples in group 5 have the shortest recurrence time.
(C) Kaplan–Meier overall survival curves of group 1–5. Here ʻ*’ represents 0.01 < p ≤ 0.05, and ʻ**’ represents 0.001 < p ≤ 0.01. If there is
no labeling of the significance level, it means the difference is not significant. Significant p-values in (C) are as follows: p(G1,G2) < 0.01,
p(G1,G3) < 0.0001, p(G1,G4) < 0.0001, p(G1,G5) < 0.01, p(G2,G3) < 0.05, p(G2,G4) < 0.01.
www.oncotarget.com
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We then captured these results by a Gaussian
model of the modularity distribution of each group, with
mean and standard deviation computed from individual
modularity of each group, Figure 6D and 6E, middle
panel. Based on (eq.4) and (eq.5) defined in the ‘Materials
and Methods’ section, the probability of survival over 24
months and the probability of no recurrence in 12 months
was calculated, Figure 6D and 6E, right panel. This simple
model was able to recapitulate the trend observed in the
clinical data, Figure 6D and 6E, left panel. The modularity
range in these two plots was selected as 0.248 – 0.652
to match with the observed individual modularity values.
Individual modularity showed significant potential as a
predictor of patients’ survival or tumor recurrence. A high
value of individual modularity was predictive of poor
prognosis, with values of M > 0.6 correlated to survival
and non-recurrence probabilities less than 0.4.

phosphorylation (OXPHOS) play important roles in
orchestrating cancer metabolism [12–15, 17, 18, 32].
Previously, Yu et al. developed the AMPK and HIF1 signatures to quantify the activities of metabolism
phenotypes in hepatocellular carcinoma (HCC) [20].
There was a visually apparent modular pattern of gene
expression due to the strong anti-correlation between
AMPK and HIF-1 activities in HCC. In this work, we
analyzed the gene expression pattern of metabolic genes
in HCC in term of modularity and studied its correlation
with metabolism phenotypes, tumor stages, metastatic
potentials and tumor recurrence.
The analyses of modularity in the glycolysis,
hybrid and OXPHOS metabolism phenotypes; stage
I and stage II–IV tumor stages; and varying tumor
metastatic potentials and recurrence status consistently
showed that a higher modularity of the AMPK and HIF-1
downstream gene network corresponded to worse overall
survival results of HCC patients. For example, a group
of samples characterized by high glycolytic activity
showed significantly higher modularity than a group
of samples characterized by high OXPHOS activity,

DISCUSSION
Metabolic reprogramming is an emerging hallmark
of cancer [10, 11]. Both aerobic glycolysis and oxidative

Figure 6: Individual modularity. (A–C) Individual modularity results show the same trend of modularity with metabolism types, stages,

and metastatic potential. Pearson correlation between individual modularity and eight-gene metastatic potential r = 0.46, p < 0.0001 (C). (D) Left:
probability of survival longer than 24 months derived from data. Middle: Gaussian distribution of modularity values for the two groups. Right:
same probability based on Gaussian model. (E) Left: probability of no recurrence in 12 months derived from data. Middle: Gaussian distribution
of modularity values for the two groups. Right: same probability based on Gaussian model. Here ʻ*’ represents 0.01 < p ≤ 0.05, ʻ**’ represents
0.001 < p ≤ 0.01, and ʻ***’ represents p ≤ 0.001. If there is no labeling of the significance level, it means the difference is not significant.
www.oncotarget.com
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and worse prognosis. The result is consistent with the
experimental observation that hepatocarcinogenesis
initiates with a switch of metabolism from OXPHOS to
glycolysis, and glycolysis is maintained to facilitate the
aggressive features of advanced HCCs [33, 34]. Similarly,
comparison of HCC samples at stage I to that at stage
II–IV showed that HCC samples at stage II–IV have a
more modular expression pattern of metabolic genes and
worse survival prognosis. Additionally, HCC patients
with a higher metastatic potential had a more modular
expression pattern of metabolic genes and worse survival
prognosis. Finally, patients with tumor recurrence within a
given time had a higher modularity of the metabolic gene
network and worse prognosis than patients with no tumor
recurrence.
One interesting phenomena in this work is the
non-monotonic relation between modularity and tumor
progression as shown in Figure 5B. Modularity increased
first and then decreased. This result is similar to the trend
observed in a previous study of acute myeloid leukemia
[9]. We argue that at early stages of tumor progression, a
modular pattern of cancer-associated gene interactions is
organized by tumor cells, so that they can counteract the
host defense systems. At later stages of tumor progression,
cancer has overcome the host defenses, and a high value
of modularity is no longer selected for. The results here
suggest that the relation between modularity and tumor
aggressiveness is mediated by tumor progression. For
most of the patient’s history, a higher modularity indicates
higher risk. Only when tumor progression has reached a
very late stage, may a lower modularity indicate higher
risk. Therefore, an accurate interpretation of modularity
should take progression stage into consideration.
We further investigated the relation between
modularity and tumor recurrence time in three subsets:
HCC samples with glycolysis phenotype, at stage II–IV,
and with high metastatic potential determined by the eightgene signature (Supplementary Figure 4). These groups
were chosen as they tend to be under highly stressful
conditions such as hypoxia due to rapid proliferation
of tumor and response from the host immune systems
during metastasis. The glycolysis group had 37 patients
that recurred. After discarding 2 samples with the shortest
recurrence time, the rest were distributed into 5 equal
size groups. A similar procedure was taken for the other
two groups. Again, HCC samples in group 1 had the
longest recurrence time and HCC samples in group 5 had
the shortest recurrence time. Survival curves for each
group were also plotted. We found that the correlation
of higher modularity with worse prognosis exists for the
roughly ~60% (top 3 groups) of patients with the longest
recurrence time in all three cases. Interestingly, a reversal
of this correlation occurs at about the same recurrence
time: 9.1 months for the glycolysis group, 6.4 months
for the stage II-IV group, and 7.9 months for the high
metastatic potential group. These times are consistent with
www.oncotarget.com

the reversal of the correlation at 8 months found among all
recurred patients (Figure 5B).
Taken together, these results show that modularity
is selected for under the stressful conditions of early to
mid-progression. That is, more aggressive early and midprogression tumors, as judged by decreased host survival
probability, have higher modularity of metabolic genes.
These results confirm our previous hypothesis that more
malignant tumors are usually characterized by a more
modular expression pattern of cancer-associated genes
[8, 9]. We predict that higher modularity increases
the fitness of tumors because metabolic networks are
typically under increased stress in HCC tumor cells
[35]. Thus, tumors with a more modular metabolic gene
network typically are more fit and are more likely to
overcome the body’s defenses. Once the transition to
imminent recurrence is achieved, the selection strength for
modularity is no longer present, and the observed values
of modularity decrease.
Notably, modularity is predictive of prognosis
independent of metastatic status of HCC samples. We
analyzed the association of modularity with different
metabolism phenotypes, varying stages, and tumor
recurrence for the HCC patients with no distant metastasis,
cancer staging ‘M0’, i.e. no spread of tumor to other parts
of the body, Supplementary Figures 5–8. More modular
gene expression patterns of metabolic genes were observed
for HCC samples in the glycolysis phenotype than in the
OXPHOS phenotype, Supplementary Figure 6, at stage II–
IV than that at stage I, Supplementary Figure 7, and with
tumor recurrence than without recurrence, Supplementary
Figure 8. These results support the conclusion that
modularity is a fundamental order parameter correlated
with tumor aggressiveness.
To the best of our knowledge, this is the first effort
to evaluate aggressiveness of HCC samples by evaluating
the expression pattern of metabolic genes in terms of
modularity. Further work can extend the modularity
concept to different types of tumors. There are at least two
avenues for the improvement of the present study. First, a
different set of parameters used in calculating individual
modularity might affect the predictive efficiency. We list
in Supplementary Table 2 the parameters for calculating
individual modularity using iterative sparse principal
components analysis (ITSPCA). Varying values of these
standard parameter gave similar results, but with a weaker
signal. We therefore believe that the chosen parameter
set works well and keeps most of the signal. Future work
could quantify the signal as a function of the parameter set
to improve the predictive power of individual modularity.
Second, temporal expression profiles of the metabolic
genes in HCC samples from individual patients may
further power the personalized prognosis.
In summary, modular interactions between
metabolic genes in HCC play a key role in HCC prognosis.
HCC patients with higher individual modularity have a
15022
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higher risk of tumor recurrence and poorer prognosis.
There are several possible clinical applications from
the individual modularity. First, prediction of patient
survival and recurrence probabilities with individual
modularity can adjust the choice of appropriate therapies.
Second, key driver genes promoting HCC progression
could be potentially identified, e.g. a hub node gene that
strengthens intracommunity interactions and increases
modularity. Third, drug treatment efficacy could be
evaluated by testing the ability of drugs to disrupt the
modular interactions between cancer-associated genes.
A novel approach for drug design could target genes that
significantly contribute to the increase of modularity of the
cancer-associated gene network.

x→

371 primary HCC samples
RNA-Seq data for 373 hepatocellular carcinoma
(HCC) samples, which contain the gene expression of
33 AMPK downstream genes and 23 HIF-1 downstream
genes, were obtained from TCGA at cBioPortal [36, 37].
A full list of the AMPK and HIF-1 downstream genes can
be found in Supplementary Materials Section 1. Among
the 373 HCC samples, 371 primary tumor samples were
used for subsequent analysis, and 2 recurrent tumor
samples were excluded.

Calculation of group modularity
Modularity of a given graph Aij was defined as

1
∑ ∑
2e modules i. j within
this module


ai a j 
 Aij −

2e  (1)


where Aij is 1 if there is an edge between nodes i
and j and 0 otherwise, the value of ai = Σj Aij is the degree
of node i, and e = ½ Σi ai is the total number of edges.
This definition can be extended to unsigned weighted
graphs, where Aij is the weight of the edge between nodes
i and j and where Aij > 0. Here the subscript ‘G’ denotes
group modularity. We applied Newman’s algorithm [22]
to graph Aij to calculate modularity. This algorithm found
the partition of 56 genes into modules that maximized
modularity. This maximized modularity was used as the
final modularity value for data analysis.
To calculate modularity of HCC samples grouped by
metabolism phenotypes, tumor stages, metastatic potential,
or recurrence status, the RNA-seq data of each of the 56
AMPK and HIF-1 downstream genes were transformed by
log2 and normalized, i.e.
www.oncotarget.com

σ(log 2 ( x + 1))

where x represents the expression of each gene,
log 2 ( x + 1) is the mean of the log2 transformed values
across all patients’ expression of this gene, and σ(log 2 ( x + 1))
is the standard deviation of the log2 transformed values.
The metabolic gene network for each group was
defined by setting the 56 genes as the nodes and the
Pearson correlation coefficient between genes as the link
weights. The resulting network was represented by a
56*56 correlation matrix C. Since the above definition of
modularity is for an unsigned graph, and since we regard
negative correlations as weak links between genes, the
whole matrix was shifted as C′ = (C+1)/2. We then set the
diagonal elements of C′ to 0 to eliminate self-loops and
used the Newman algorithm to calculate the modularity
of this matrix C′.
To compare modularity between different
patient groups, e.g. glycolysis versus OXPHOS, the
bootstrapping method was used. This method takes the
observed individual gene expression values as the most
representative measure of the underlying distribution of
expression values. That is, the distribution of expression
values is taken as a sum over δ functions at the observed
values. Predictions are computed from samples taken
from this estimated distribution. For example, for the
glycolysis group of 75 patients, the gene expression
correlation matrix was calculated by randomly taking
expression values from the 75 patients with replacement.
The modularity of this correlation matrix was computed
as described above. This sampling process was repeated
10 000 times to obtain 10 000 modularity values for the
glycolysis group. Mean modularity and standard error
were then obtained. This same procedure was used
to compute modularity for each of the other groups.
Calculation of p-values is described in subsection ʻp-value
calculation’.

MATERIALS AND METHODS

=
MG

log 2 ( x + 1) − log 2 ( x + 1)

Calculation of individual modularity
Typically, for each patient there is one expression
value for each gene, and no correlation between genes
based upon only a single patient’s data can be computed.
We propose, therefore, to define the link between gene i
and gene j of patient α as

(

liα, j = exp − X α , i − X α , j / σ

) (2)

where X is the expression of gene i of patient ⍺,
and σ is the standard deviation of X α , i − X α , j averaged
across all pairs of genes and all patients, with σ = 57 887
in our case. This definition considers the link between
gene i and gene j weak if the distance between them,
α, i
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Mi. P-values were calculated using the method described
in subsection ʻp-value calculation’.

i.e., X α , i − X α , j is large. The scaling by σ ensures that
X α , i − X α , j / σ remains within a reasonable order of
magnitude.
Unlike the group modularity case, having only 56
expression values for each individual means the noise in
the data has a greater impact on the calculated modularity
values. Thus, a better way of filtering noise is needed. A
standard approach is to reconstruct the data based only
on cleaned leading eigenvectors. We utilized the iterative
thresholding sparse PCA (ITSPCA) algorithm for this
purpose [38]. The algorithm starts by keeping only the top
eigenvectors. To separate signal and noise, such that signal
is defined as above a threshold, a wavelet transformation
is used, see Supplementary Materials section ʻdiscrete
wavelet transform’, Supplementary Figure 1 and
Supplementary Table 1. Data that were dense in real
space became sparse in wavelet space, and a cutoff was
then applied in wavelet space to eliminate the noise. The
standard wavelet transformation algorithm requires that
the number of entries be a power of two. Zero-padding
was applied to the input data matrix so that it became
a 371 × 64 matrix, with the last 8 columns containing
only zeros. The ITSPCA algorithm output the cleaned
56 × n matrix version of the leading eigenvectors Pn ,
which is used to reconstruct the raw data as

Definition of probability of surviving longer than
24 months based on individual modularity
psurvival,24 ( M i ) =



(4)

where Nsurvived,24 and Ndeceased,24 are the numbers of patients
that lived longer than 24 months and deceased within 24
months, respectively. Here fsurvived,24 and fdeceased,24 are the
probability density functions of the modularity distribution
of survived and deceased group, respectively. Given
modularity Mi, we calculated psurvival, 24 and thus obtained
the probability curve of surviving more than 24 months.

Definition of probability of no recurrence in 12
months based on individual modularity
pno recurrence,12 ( M i ) =

N no recurrence,12 f no recurrence, 12 ( M i )

N no recurrence,12 f no recurrence, 12 ( M i ) + N recurrence,12 f recurrence, 12 ( M i ) (5)

where Nno recurrence,12 and Nrecurrence,12 are the numbers of
patients that remained disease free for more than 12
months and those that recurred within 12 months,
respectively. Here fno recurrence,12 and frecurrence,12 are the
probability density functions of the modularity distribution
of disease-free and recurred group, respectively. Given
modularity Mi, we calculated pno recurrence,12 and thus obtained
the probability curve of no recurrence within 12 months.

X ' = XPn PnT (3)

where X is the original raw data matrix, and X’ is
the reconstructed matrix that has the same dimension
as X. The cleaned data X’ should contain mostly signal
and much less noise than X, and therefore X’ was used
in calculation of links (eq.2). Note that, unlike the
group modularity calculation, X is based on the raw data
without taking a logarithm. This is because we believe
that noise had already been filtered out by ITSPCA, and
taking the logarithm would only weaken the signal. See
Supplementary Table 2 for chosen input parameters of the
ITSPCA algorithm.
After determining X’, we computed the individual
gene network linkage based on (eq.2). We then applied
the binarization step where the top 5.6% edges (178
edges) were set to 1 and the rest set to zero. According
to our previous work [31], this binarization step increases
the signal-to-noise ratio without discarding important
information. The Newman algorithm was used to compute
modularity for each patient, Mi. We computed 10, 000
bootstrap samples of the individual modularities of each
group, calculating the mean of the individual modularities
in each sample. For the glycolysis group, for example,
there are 75 individual modularities in each bootstrap
sample. The average and standard deviation of the means
were plotted in the bar plots. Note that this average is the
same as the one directly calculated from the vector of Mi,
and this standard deviation is the same as the standard
error of the mean directly calculated from the vector of
www.oncotarget.com

N survived,24 f survived, 24 ( M i )

N survived,24 f survived, 24 ( M i ) + N deceased,24 f deceased, 24 ( M i )

P-value calculation
Given two samples x1 and x2, a standard way to test
for equal means is a two-sample t test. However, in the
current research, it is often the case that we do not have
direct access to x1 and x2, or that the original x1 and x2 are of
no interest. For example, in the case of comparing group
modularity, e.g. Figures 2B, 3A, the only available values
are vectors of the bootstrapped modularity of each group.
The original x1 and x2 , which are the gene expression of
samples in the group, were of no interest.
We therefore perform a standard Monte Carlo test of
p-values. Given input data x1, x2, and function of interest
F, we perform B bootstrap samples of the function with
replacement, obtaining vectors F1 and F2. Each element of
Fi was obtained by calculating F( xib ), where xib is the
bootstrapped sample of xi in bootstrap b (b = 1,2, …, B).
We assume the average of F1 is greater than F2. We define
uobs= F1 − F2
and shift the bootstrap samples as
z = (F̅ 1 + F̅ 2)/2
F1* = F1 − F1 + z
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We define for each bootstrap sample b
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The bootstrapping process gives the distribution
of F1 and F2. Note that z is the mean of the concatenated
vector of F1 and F2, and B is set to 10 000 in all cases.
The null hypothesis H0 is that F1 and F2 have equal means,
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For bar plots involving group modularity, x1 and x2
are gene expressions of group 1 and group 2, and F is the
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